NEW YORK (GenomeWeb News) – Exact Sciences today reported a sharp increase in its revenues for the third quarter and cut its net loss by two-thirds year over year.

The Madison, Wis.-based molecular diagnostics firm reported total revenues of $1.3 million for the three-month period ended Sept. 30. It brought in product royalty revenues of $9,000 and license fees of $1.2 million, compared to license fees of $337,000 in the third quarter of 2008. In addition, in last year's third quarter the company paid out $1 million in royalty fees.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.